| Literature DB >> 28367281 |
Chang Hee Kwon1, Seong-Hyop Kim2.
Abstract
The incidence of intraoperative arrhythmia is extremely high, and some arrhythmias require clinical attention. Therefore, it is essential for the anesthesiologist to evaluate risk factors for arrhythmia and understand their etiology, electrophysiology, diagnosis, and treatment. Anesthetic agents reportedly affect normal cardiac electrical activity. In the normal cardiac cycle, the sinoatrial node initiates cardiac electrical activity through intrinsic autonomous pacemaker activity. Sequential atrial and ventricular contractions result in an effective cardiac pumping mechanism. Arrhythmia occurs due to various causes, and the cardiac pumping mechanism may be affected. A severe case may result in hemodynamic instability. In this situation, the anesthesiologist should eliminate the possible causes of arrhythmia and manage the condition, creating hemodynamic stability under proper electrocardiographic monitoring.Entities:
Keywords: Anesthesia; Cardiac arrhythmias; Cardiac cycle
Year: 2017 PMID: 28367281 PMCID: PMC5370296 DOI: 10.4097/kjae.2017.70.2.120
Source DB: PubMed Journal: Korean J Anesthesiol ISSN: 2005-6419
Fig. 1Electrocardiograph (ECG) and cardiac action potential of the ventricle.
Anti-arrhythmic Agents
| Class | Basic mechanism | Comments | Drugs | Uses |
|---|---|---|---|---|
| I | Sodium-channel blockade | Reduce phase 0 slope and peak of action potential | ||
| IA | Moderate | Moderate reduction in phase 0 slope; increase action potential duration; increase effective refractory period. | Quinidine, procainamide, disopyramide | Ventricular arrhythmias, atrial fibrillation |
| IB | Weak | Small reduction in phase 0 slope; reduce action potential duration; decrease effective refractory period. | Lidocaine, tocainide, mexiletine | Ventricular arrhythmias |
| IC | Strong | Pronounced reduction in phase 0 slope; no effect on action potential duration or effective refractory period. | Flecainide, propafenone | Paroxysmal atrial fibrillation |
| II | Beta-blockade | Block sympathetic activity; reduce rate and conduction | Acebutolol, atenolol, bisoprolol, esmolol, metoprolol, nadolol, propranolol, carvedilol, labetalol | |
| III | Potassium-channel blockade | Delay repolarization (phase 3) and thereby increase action potential duration and effective refractory period | Sotalol, dofetilide, ibutilide, bretylium, amidodarone | Ventricular arrhythmias, atrial fibrillation |
| IV | Calcium-channel blockade | Block L-type calcium-channels; most effective at sinoatrial and atrioventricular nodes; reduce rate and conduction | Amlodipine, felodipine, isradipine, nicardipine, nifedine, diltiazem, verapamil |
Fig. 2Atrioventricular block (A), paroxysmal supraventricular tachycardia (B), atrial flutter (C), atrial fibrillation (D).
Fig. 3Premature ventricular contraction (A), ventricular tachycardia (B), ventricular fibrillation (C).
Fig. 4Torsade de pointes.
Fig. 5Artifacts.